Flash-spelare saknas/Javascript är inte aktiverat

Welcome to Dilafor

Dilafor develops pharmaceutical products from heparin derivatives with low anticoagulant activity.
The company has a balanced product portfolio representing some highly promising ideas and innovations. Each of our projects addresses an important and unfulfilled medical need.

All our drug development projects are based on the use of Low Anticoagulant Heparin (LAH). Although standard heparin has numerous biological functions, its potential development as a treatment for indications other than those currently approved is limited by its anticoagulative properties. Dilafor has produced several forms of LAH.
Two products are presently in development; tafoxiparin, for the prevention and normalization of protracted labor, has recently completed a Phase II Proof of Concept clinical trial in Phase II. Promising results were found in the trial, where 263 women were included. Statistically significant less women were found in the group that was treated with tafoxiparin, in comparison with placebo. A Phase I "First In Man" trial of DF02, for the treatment of severe malaria, was successfully completed in QIII 2009. This will be followed by a proof of concept trial in Phase II.

Further New Chemical Entities similar to tafoxiparin and DF02 are being developed for other indications.

Malaria

Learn more about our work to fight malaria.

Obstetrics

Learn more about our work in obstetrics.

NEWS

2009-12-17
Dilafor adds important capabilities to the board

2009-10-12
Potential Treatment for Severe Malaria Completes Phase I Study

A significant milestone has been passed with the completion of a Phase I study for a potential new treatment for severe malaria. The recently completed Phase I study has proven that the new compound DF02 is safe and well tolerated. With this result, work towards developing this in to a new drug that can save
lives can proceed.

2009-09-04
Promising Results from Phase II Trial Show New Treatment from Dilafor Prevents Protracted Labor in Childbirth

STOCKHOLM - September 4, 2009. Dilafor AB, a Karolinska Development portfolio company, today announced it has concluded a Phase II study of the drug candidate tafoxiparin (DF01), a new drug substance developed for the prevention of protracted labor during childbirth. Results from the study indicate that tafoxiparin reduces the incidence of protracted labor. The treatment, which was administered during the last phase of pregnancy, was also shown to be safe and well tolerated.